Navigation Links
SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Date:3/27/2008

Company Presents Today at BioCentury Future Leaders Conference

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) is providing an update today on the SGX523 clinical program.

In January 2008, the Company initiated two parallel, multi-center Phase 1 clinical trials of SGX523 in patients with solid tumor cancers. The first trial has been designed to examine twice daily, oral dosing on a continuous 28-day cycle and the second trial has been designed to examine interrupted dosing (a repeating 21 day cycle of 14 days on therapy followed by 7 days off).

In both trials, the Company observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. The interrupted dosing trial started at a higher dose than the continuous dosing trial and no patients are currently receiving treatment on the interrupted dosing trial. In the continuous dosing trial, patients are continuing to be treated at a lower dose level, and the Company is evaluating the safety and efficacy of treatment at that dose level.

"From the initial clinical data, the profile of SGX523 appears to be different than the preclinical data would suggest," said Mike Grey, president and chief executive officer of SGX Pharmaceuticals. "On the continuous dosing trial, patients continue on study at the initial dose and we may explore whether alternative doses and schedules are safe and efficacious. We continue the preclinical development of the BCR-ABL inhibitor SGX393 and the second MET inhibitor SGX126. In addition, we are targeting the identification of two development candidates this year from our drug discovery programs to further enhance our pi
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
4. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
5. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
8. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
9. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
10. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for the ... Tech Awards. , Now in its 22nd year, this premier awards event celebrates the ... the nation and around the world. The OC Tech Alliance will announce all winners ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... by Strong Revenue Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q1 2008 (millions) Q1 2007 Comparison ... 164.5% increase Naglazyme Net Product Revenue ... Aldurazyme (net sales by Genzyme) $36.8 ...
... ... - Product revenues increased 30% to a record $59.7 million ... 28,600 new pulse oximeters ... April 29, 2008 Masimo,Corporation (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion ...
... transmit medical images via cellular phones that has ... researcher has the potential to provide sophisticated radiological diagnoses ... lacking access to such technology. This would include millions ... areas of developed countries who live considerable distances from ...
Cached Biology Technology:BioMarin Announces First Quarter 2008 Financial Results 2BioMarin Announces First Quarter 2008 Financial Results 3BioMarin Announces First Quarter 2008 Financial Results 4BioMarin Announces First Quarter 2008 Financial Results 5BioMarin Announces First Quarter 2008 Financial Results 6BioMarin Announces First Quarter 2008 Financial Results 7BioMarin Announces First Quarter 2008 Financial Results 8BioMarin Announces First Quarter 2008 Financial Results 9BioMarin Announces First Quarter 2008 Financial Results 10BioMarin Announces First Quarter 2008 Financial Results 11Masimo Reports First Quarter 2008 Financial Results 2Masimo Reports First Quarter 2008 Financial Results 3Masimo Reports First Quarter 2008 Financial Results 4Masimo Reports First Quarter 2008 Financial Results 5Masimo Reports First Quarter 2008 Financial Results 6Masimo Reports First Quarter 2008 Financial Results 7Masimo Reports First Quarter 2008 Financial Results 8Masimo Reports First Quarter 2008 Financial Results 9Masimo Reports First Quarter 2008 Financial Results 10Researchers develop method for transmitting medical images via cell phones 2Researchers develop method for transmitting medical images via cell phones 3Researchers develop method for transmitting medical images via cell phones 4
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... from the University of Santiago de Compostela (USC) have ... The results show that the principal goal of young ... The most antisocial among them place greater importance on ... most importance on are to do with leaving home, ...
... Research currently being undertaken at the University of ... Abdominal Aortic Aneurysms (AAA) in men. In her ... into the causes of the male predominance of AAA, ... disease. Preliminary results from the study will be showcased ...
... KNOXVILLE -- By examining 800,000-year-old polar ice, scientists increasingly are ... melt and that carbon dioxide has become more abundant in ... Jrme Chappellaz has been examining ice cores collected from deep ... studies on the interconnecting air spaces of old snow -- ...
Cached Biology News:Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2Scientist links increase in greenhouse gases to changes in ocean currents 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: